Article PDF first page preview

First page of Acute kidney injury in a cancer patient exposed to relugolix and abiraterone

Introduction: Abiraterone acetate is an inhibitor of androgen biosynthesis and is approved as a treatment for metastatic castration-resistant and metastatic castration-sensitive prostate cancer. Neither relugolix nor abiraterone is known to cause acute kidney injury. Case Presentation: A 72-year-old Caucasian man with metastatic prostate cancer presented with non-oliguric severe acute kidney injury (AKI) one week after receiving simultaneous therapy with relugolix and abiraterone. The patient had been on abiraterone for three weeks. His physical examination was unremarkable. Blood work on admission revealed hypocalcemia, and elevated creatinine at 3.6 mg/dL. A kidney biopsy confirmed the diagnosis of a high-grade subacute tubular damage, most likely due to nephrotoxicity. The patient did not respond to intravenous isotonic fluids, the discontinuation of relugolix, abiraterone, and rosuvastatin, as well as to hemodialysis. He died 22 days after hospital admission. Conclusion: We report the first case of biopsy-proven drug-induced AKI in a cancer patient acutely exposed to relugolix and abiraterone. Whether one of these drugs individually, or their combination, was the cause of the AKI is unknown. Nonetheless, our report is hypothesis-generating for further investigations on the effect of these drugs.

Journal Section:
Case Report
This content is only available via PDF.
The Author(s). Published by S. Karger AG, Basel
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License .
Attribution-NonCommercial